Ftse Mib
34.150,97
0,48%
DAX
18.281,73
0,60%
S&P 500
5.180,74
1,03%
NASDAQ
16.349,25
0,00%
Bitcoin
63.630,98
0,72%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Candel Therapeutics Inc (CADL) Candel Therapeutics Inc (CADL) Notizie

Candel Therapeutics Inc

CADL
8,9469
0,0969 (1,09%)
Pre Mercato
Ultimo aggiornamento: 14:00:18
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/4/202414:00GLOBECandel Therapeutics Announces Upcoming Presentations at the..
11/4/202415:00GLOBECandel Therapeutics Receives FDA Orphan Drug Designation for..
09/4/202414:00GLOBECandel Therapeutics Presents Preclinical Data at AACR on..
04/4/202414:00GLOBECandel Therapeutics Announces Positive Interim Data from..
28/3/202421:05GLOBECandel Therapeutics Announces Oral Presentation During the..
28/3/202413:05GLOBECandel Therapeutics Reports Fourth Quarter and Full Year..
06/3/202414:00EDGAR2Form 8-K - Current report
05/3/202422:30GLOBECandel Therapeutics Announces an Upcoming Presentation at..
13/2/202415:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/2/202413:45EDGAR2Form 8-K - Current report
13/2/202413:30GLOBECAN-3110 Receives FDA Fast Track Designation for Treatment..
05/2/202414:00GLOBECandel Therapeutics Sets Path to Success: Recent..
19/1/202414:30EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/1/202422:30EDGAR2Form 8-K - Current report
03/1/202414:30EDGAR2Form 8-K - Current report
12/12/202314:58DJNCandel Therapeutics Shares Soar After FDA Fast Track of..
12/12/202314:30EDGAR2Form 8-K - Current report
12/12/202314:00GLOBECandel Therapeutics Receives FDA Fast Track Designation for..
30/11/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:00EDGAR2Form 8-K - Current report
28/11/202315:00GLOBECandel Therapeutics Announces Restructuring to Prioritize..
21/11/202323:00EDGAR2Form 8-K - Current report
09/11/202314:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202314:16EDGAR2Form 8-K - Current report
09/11/202314:00GLOBECandel Therapeutics Reports Third Quarter 2023 Financial..
06/11/202314:53EDGAR2Form 8-K - Current report
06/11/202314:15EDGAR2Form 8-K - Current report
04/11/202313:00GLOBECandel Therapeutics Presents Preclinical Data from its..
03/11/202317:00GLOBECandel Therapeutics Announces Initial Positive Interim Data..
18/10/202317:31EDGAR2Form 8-K - Current report
18/10/202317:00GLOBECandel Therapeutics Announces Nature Publication Showing..
27/9/202315:40GLOBECandel Therapeutics Announces Three Abstracts Accepted for..
26/9/202314:30EDGAR2Form 8-K - Current report
26/9/202314:00GLOBECandel Therapeutics Reports Encouraging Initial Survival..
06/9/202314:00GLOBECandel Therapeutics to Participate in the H.C. Wainwright..
10/8/202314:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202314:15EDGAR2Form 8-K - Current report
10/8/202314:00GLOBECandel Therapeutics Reports Second Quarter 2023 Financial..
02/8/202314:00GLOBECandel Therapeutics to Participate in the Canaccord Genuity..
29/6/202315:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202315:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202315:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202314:31EDGAR2Form 8-K - Current report
13/6/202314:00GLOBECandel Therapeutics Announces It Expects to Report Topline..
08/6/202314:00GLOBECandel Therapeutics Appoints Experienced Manufacturing..
Apertura: Min: Max:
Chiusura: 8,85

La tua Cronologia

NASDAQ
CADL
Candel Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network